Efficient Delivery of Therapeutic Agents by Using Targeted Albumin Nanoparticles

Advances in Protein Chemistry and Structural Biology

Volumn 98, Issue , 2015, Pages 121-143

  Kouchakzadeh, Hasan ^a   Safavi, Maryam Sadat ^a   Shojaosadati, Seyed Abbas ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Abraxane ; Active targeting; Albumin nanoparticles; Desolvation; EPR effect; Monoclonal antibody; NAB technology

Indexed keywords

10 HYDROXYCAMPTOTHECIN; ALBUMIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CURCUMIN; DACARBAZINE; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; FOLIC ACID; GEMCITABINE; METHOTREXATE; NANOCARRIER; NANOPARTICLE; OBIDOXIME; OSTEONECTIN; PACLITAXEL; POLO LIKE KINASE 1; TRANSFERRIN; ALBUMINOID; MONOCLONAL ANTIBODY;

ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG RELEASE; EMULSION; GELATION; HEAD AND NECK CANCER; HUMAN; KAPOSI SARCOMA; METASTATIC MELANOMA; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; TRANSCYTOSIS; CHEMICAL PHENOMENA; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; ULTRASTRUCTURE;

ALBUMIN-BOUND PACLITAXEL; ALBUMINS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; EXTRACELLULAR MATRIX; FOLIC ACID; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASMS; PACLITAXEL; TRANSFERRIN;

EID: 84956695887     PISSN: 18761623     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.apcsb.2014.11.002     Document Type: Chapter

References (94)

1. Agarwal, A., Lvov, Y., Sawant, R., & Torchilin, V. (2008). Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology. Journal of Controlled Release, 128(3), 255-260.
2. Agrawal, S., & Kandimalla, E. R. (2000). Antisense therapeutics: Is it as simple as complementary base recognition? Molecular Medicine Today, 6(2), 72-81.
3. Altintas, I., Heukers, R., Van der Meel, R., Lacombe, M., Amidi, M., Van Bergen En Henegouwen, P. M. P., et al. (2013). Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. Journal of Controlled Release, 165(2), 110-118.
4. Anhorn, M. G., Mahler, H.-C., & Langer, K. (2008). Freeze drying of human serum albumin (HSA) nanoparticles with different excipients. International Journal of Pharmaceutics, 363(1-2), 162-169.
5. Arnedo, A., Espuelas, S., & Irache, J. (2002). Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. International Journal of Pharmaceutics, 244(1-2), 59-72.
6. Arnedo, A., Irache, J. M., González Gaitano, G., Valgañón, M., & Espuelas, S. (2003). Bovine serum albumin modified the intracellular distribution and improved the antiviral activity of an oligonucleotide. Journal of Drug Targeting, 11(4), 197-204.
7. Arnedo, A., Irache, J. M., Merodio, M., & Espuelas Millán, M. S. (2004). Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. Journal of Controlled Release, 94(1), 217-227.
8. Beltinger, C., Saragovi, H. U., Smith, R. M., LeSauteur, L., Shah, N., DeDionisio, L., et al. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. The Journal of Clinical Investigation, 95(4), 1814-1823.
9. Bertino, J. R. (1993). Ode to methotrexate. Journal of Clinical Oncology, 11(1), 5-14.
10. Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014). Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Advanced Drug Delivery Reviews, 66, 2-25.
11. Bertucci, C., & Domenici, E. (2002). Reversible and covalent binding of drugs to human serum albumin: Methodological approaches and physiological relevance. Current Medicinal Chemistry, 9(15), 1463-1481.
12. Carter, D. C., He, X. M., Munson, S. H., Twigg, P. D., Gernert, K. M., Broom, M. B., et al. (1989). Three-dimensional structure of human serum albumin. Science (New York, NY), 244(4909), 1195-1198.
13. Danesi, R., Fogli, S., Gennari, A., Conte, P., & Del Tacca, M. (2002). Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clinical Pharmacokinetics, 41(6), 431-444.
14. Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135-146.
15. Daniels, T. R., Delgado, T., Helguera, G., & Penichet, M. L. (2006). The transferrin receptor. Part II: Targeted delivery of therapeutic agents into cancer cells. Clinical Immunology, 121(2), 159-176.
16. De Vries, E. G. E., & Willemse, P. H. B. (2002). Cancer chemotherapy and biotherapy: Principles and practice. Annals of Oncology, 13(8), 1325.
17. Desai, N. (2012). Challenges in development of nanoparticle-based therapeutics. The AAPS Journal, 14(2), 282-295.
18. Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., et al. (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clinical Cancer Research, 12(4), 1317-1324.
19. Desai, N., Trieu, V., Yao, R., et al. (2003). Evidence of greater antitumor activity of ceremophorefree nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol: Role of a novel albumin transporter mechanism. In 26th annual San Antonio Breast Cancer Symposium. USA: San Antonio.
20. Ding, D., Tang, X., Cao, X., Wu, J., Yuan, A., Qiao, Q., et al. (2014). Novel self-assembly endows human serum albumin nanoparticles with an enhanced antitumor efficacy. AAPS Pharm Sci Tech, 15(1), 213-222.
21. Dobrovolskaia, M. A., & McNeil, S. E. (2007). Immunological properties of engineered nanomaterials. Nature Nanotechnology, 2(8), 469-478.
22. Dreis, S., Rothweiler, F., Michaelis, M., Cinati, J., Jr., Kreuter, J., & Langer, K. (2007). Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. International Journal of Pharmaceutics, 341, 207-214.
23. Elsadek, B., & Kratz, F. (2012). Impact of albumin on drug delivery-New applications on the horizon. Journal of Controlled Release, 157(1), 4-28.
24. Elzoghby, A. O., Samy, W. M., & Elgindy, N. a. (2012). Albumin-based nanoparticles as potential controlled release drug delivery systems. Journal of Controlled Release, 157(2), 168-182.
25. Fanciullino, R., Ciccolini, J., & Milano, G. (2013). Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs. Critical Reviews in Oncology/Hematology, 88, 504-513.
26. Fasano, M., Curry, S., Terreno, E., Galliano, M., Fanali, G., Narciso, P., et al. (2005). The extraordinary ligand binding properties of human serum albumin. IUBMB Life, 57(12), 787-796.
27. Fu, Q., Sun, J., Zhang, W., Sui, X., Yan, Z., & He, Z. (2009). Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Patents on Anti-Cancer Drug Discovery, 4(3), 262-272.
28. Gallo, J. M., Hung, C. T., & Perrier, D. G. (1984). Analysis of albumin microsphere preparation. International Journal of Pharmaceutics, 22(1), 63-74.
29. Gibbs, J. B. (2000). Mechanism-based target identification and drug discovery in cancer research. Science, 287(5460), 1969-1973.
30. Gong, J., Huo, M., Zhou, J., Zhang, Y., Peng, X., Yu, D., et al. (2009). Synthesis, characterization, drug-loading capacity and safety of novel octyl modified serum albumin micelles. International Journal of Pharmaceutics, 376(1-2), 161-168.
31. Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., et al. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology, 23(31), 7794-7803.
32. Hawkins, M. J., Soon-Shiong, P., & Desai, N. (2008). Protein nanoparticles as drug carriers in clinical medicine. Advanced Drug Delivery Reviews, 60(8), 876-885.
33. He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010). Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 31(13), 3657-3666.
34. Hersh, E. M., O'Day, S. J., Ribas, A., Samlowski, W. E., Gordon, M. S., Shechter, D. E., et al. (2010). A phase II clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer, 116(1), 155-163.
35. Irache, J. M., & Espuelas, S. (2006). Albumin nanoparticles. In: C. S. S. R. Kumar (Ed.), Biological and pharmaceutical nanomaterials, Nanotechnologies for the life sciences: Vol. 2 (pp. 185-218). Wiley-VCH.
36. Jiang, Y., Liang, M., Svejkar, D., Hart-Smith, G., Lu, H., Scarano, W., et al. (2014). Albumin-micelles via a one-pot technology platform for the delivery of drugs. Chemical Communications (Cambridge, England), 50(48), 6394-6397.
37. Jordan, M. A., & Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nature Reviews Cancer, 4(4), 253-265.
38. Karmali, P. P., Kotamraju, V. R., Kastantin, M., Black, M., Missirlis, D., Tirrell, M., et al. (2009). Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine: Nanotechnology, Biology, and Medicine, 5(1), 73-82.
39. Khlebtsov, N., & Dykman, L. (2011). Biodistribution and toxicity of engineered gold nanoparticles: A review of in vitro and in vivo studies. Chemical Society Reviews, 40(3), 1647-1671.
40. Kim, T. H., Jiang, H. H., Youn, Y. S., Park, C. W., Tak, K. K., Lee, S., et al. (2011). Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. International Journal of Pharmaceutics, 403(1-2), 285-291.
41. Kim, H., Robinson, S. B., & Csaky, K. G. (2009). Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharmaceutical Research, 26(2), 329-337.
42. Koshkaryev, A., Sawant, R., Deshpande, M., & Torchilin, V. (2013). Immunoconjugates and long circulating systems: Origins, current state of the art and future directions. Advanced Drug Delivery Reviews, 65(1), 24-35.
43. Kouchakzadeh, H., Shojaosadati, S. A., Maghsoudi, A., & Vasheghani Farahani, E. (2010). Optimization of PEGylation conditions for BSA nanoparticles using response surface methodology. AAPS Pharm Sci Tech, 11(3), 1206-1211.
44. Kouchakzadeh, H., Shojaosadati, S. A., Mohammadnejad, J., Paknejad, M., & Rasaee, M. J. (2012). Attachment of an anti-MUC1 monoclonal antibody to 5-FU loaded BSA nanoparticles for active targeting of breast cancer cells. Human Antibodies, 21(3-4), 49-56.
45. Kouchakzadeh, H., Shojaosadati, S. A., & Shokri, F. (2014). Efficient loading and entrapment of tamoxifen in human serum albumin based nanoparticulate delivery system by a modified desolvation technique. Chemical Engineering Research and Design, 92(9), 1681-1692.
46. Kouchakzadeh, H., Shojaosadati, S. A., Tahmasebi, F., & Shokri, F. (2013). Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles. International Journal of Pharmaceutics, 447(1-2), 62-69.
47. Kratz, F. (2008). Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. Journal of Controlled Release, 132(3), 171-183.
48. Kratz, F. (2014). A clinical update of using albumin as a drug vehicle-A commentary. Press release, Journal of Controlled Release, 190, 331-336.
49. Kufleitner, J., Wagner, S., Worek, F., Von Briesen, H., & Kreuter, J. (2010). Adsorption of obidoxime onto human serum albumin nanoparticles: Drug loading, particle size and drug release. Journal of Microencapsulation, 27(6), 506-513.
50. Langer, K., Anhorn, M. G., Steinhauser, I., Dreis, S., Celebi, D., Schrickel, N., et al. (2008). Human serum albumin (HSA) nanoparticles: Reproducibility of preparation process and kinetics of enzymatic degradation. International Journal of Pharmaceutics, 347(1-2), 109-117.
51. Langer, K., Balthasar, S., Vogel, V., Dinauer, N., Von Briesen, H., & Schubert, D. (2003). Optimization of the preparation process for human serum albumin (HSA) nanoparticles. International Journal of Pharmaceutics, 257(1-2), 169-180.
52. Langer, K., Coester, C., Weber, C., Von Briesen, H., & Kreuter, J. (2000). Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. European Journal of Pharmaceutics and Biopharmaceutics, 49(3), 303-307.
53. Lanza, R., Langer, R., & Vacanti, J. (Eds.), (2011). Principles of tissue engineering. China: Elsevier Academic Press.
54. Lebedeva, I., & Stein, C. A. (2001). Antisense oligonucleotides: Promise and reality. Annual Review of Pharmacology and Toxicology, 41, 403-419.
55. Li, C., Li, Y., Gao, Y., Wei, N., Zhao, X., Wang, C., et al. (2014). Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: Is the crosslinked version more advantageous? International Journal of Pharmaceutics, 468(1-2), 15-25.
56. Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. Journal of Pharmacological and Toxicological Methods, 44(1), 235-249.
57. Low, P. S., & Kularatne, S. A. (2009). Folate-targeted therapeutic and imaging agents for cancer. Current Opinion in Chemical Biology, 13(3), 256-262.
58. Ma, P., & Mumper, R. J. (2013). Paclitaxel nano-delivery systems: A comprehensive review. Journal of Nanomedicine and Nanotechnology, 4(2), 1000164.
59. Maghsoudi, A., Shojaosadati, S. A., & Vasheghani Farahani, E. (2008). 5-Fluorouracil-loaded BSA nanoparticles: Formulation optimization and in vitro release study. AAPS Pharm Sci Tech, 9(4), 1092-1096.
60. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56(2), 185-229.
61. O'Leary, J., & Muggia, F. M. (1998). Camptothecins: A review of their development and schedules of administration. European Journal of Cancer, 34(10), 1500-1508.
62. Owens, D. E., & Peppas, N. A. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics, 307(1), 93-102.
63. Patil, G. V. (2003). Biopolymer albumin for diagnosis and in drug delivery. Drug Development Research, 58(3), 219-247.
64. Pinto Reis, C., Neufeld, R. J., Ribeiro, A. J., & Veiga, F. (2006). Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2(1), 8-21.
65. Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., et al. (2013). Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Research, 73(8), 2412-2417.
66. Prados, J., Melguizo, C., Ortiz, R., Vélez, C., Alvarez, P. J., Arias, J. L., et al. (2012). Doxorubicin-loaded nanoparticles: New advances in breast cancer therapy. Anti-Cancer Agents in Medicinal Chemistry, 12(9), 1058-1070.
67. Rowinsky, E. K. (1993). Clinical pharmacology of Taxol. Journal of the National Cancer Institute Monographs, (15), 25-37.
68. Shen, Z., Li, Y., Kohama, K., Oneill, B., & Bi, J. (2011). Improved drug targeting of cancer cells by utilizing actively targetable folic acid-conjugated albumin nanospheres. Pharmacological Research, 63(1), 51-58.
69. Singal, P. K., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000). Adriamycin-induced heart failure: Mechanism and modulation. Molecular and Cellular Biochemistry, 207(1-2), 77-86.
70. Steinhauser, I. M., Langer, K., Strebhardt, K. M., & Spa, B. (2008). Effect of trastuzumabmodified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. Biomaterials, 29, 4022-4028.
71. Taheri, A., Dinarvand, R., Ahadi, F., Khorramizadeh, M. R., & Atyabi, F. (2012). The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4 T1 tumor-bearing Balb/c mice. International Journal of Pharmaceutics, 431(1-2), 183-189.
72. Taheri, A., Dinarvand, R., Atyabi, F., Ahadi, F., Nouri, F. S., Ghahremani, M. H., et al. (2011). Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with luteinizing hormone-releasing hormone (LHRH) peptide. International Journal of Molecular Sciences, 12(7), 4591-4608.
73. Takara, K., Hatakeyama, H., Kibria, G., Ohga, N., Hida, K., & Harashima, H. (2012). Sizecontrolled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. Journal of Controlled Release, 162(1), 225-232.
74. Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., et al. (2011). Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenetics and Genomics, 21(7), 440-446.
75. Tiruppathi, C., Song, W., Bergenfeldt, M., Sass, P., & Malik, A. B. (1997). Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. The Journal of Biological Chemistry, 272(41), 25968-25975.
76. Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009). Transferrin- and transferrinreceptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). European Journal of Pharmaceutics and Biopharmaceutics, 71(2), 251-256.
77. Van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & Van Gaal, E. V. B. (2013). Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Advanced Drug Delivery Reviews, 65(10), 1284-1298.
78. Van Zuylen, L., Verweij, J., & Sparreboom, A. (2001). Role of formulation vehicles in taxane pharmacology. Investigational New Drugs, 19(2), 125-141.
79. Venditto, V. J., & Szoka, F. C. (2013). Cancer nanomedicines: So many papers and so few drugs!. Advanced Drug Delivery Reviews, 65(1), 80-88.
80. von Storp, B., Engel, A., Boeker, A., Ploeger, M., & Langer, K. (2012). Albumin nanoparticles with predictable size by desolvation procedure. Journal of Microencapsulation, 29(2), 138-146.
81. Vonarbourg, A., Passirani, C., Saulnier, P., & Benoit, J.-P. (2006). Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials, 27(24), 4356-4373.
82. Wacker, M., Zensi, A., Kufleitner, J., Ruff, A., Schütz, J., Stockburger, T., et al. (2011). A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation. International Journal of Pharmaceutics, 414(1-2), 225-232.
83. Wagner, S., Rothweiler, F., Anhorn, M. G., Sauer, D., Riemann, I., Weiss, E. C., et al. (2010). Enhanced drug targeting by attachment of an anti αv integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials, 31, 2388-2398.
84. Wang, T. H., Wang, H. S., & Soong, Y. K. (2000). Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together. Cancer, 88(11), 2619-2628.
85. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971). Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical Society, 93(9), 2325-2327.
86. Weber, C., Kreuter, J., & Langer, K. (2000). Desolvation process and surface characteristics of HSA-nanoparticles. International Journal of Pharmaceutics, 196(2), 197-200.
87. Xu, R., Fisher, M., & Juliano, R. L. (2011). Targeted albumin-based nanoparticles for delivery of amphipathic drugs. Bioconjugate Chemistry, 22(5), 870-878.
88. Yan, H., Wang, L., Wang, J., Weng, X., Lei, H., Wang, X., et al. (2012). Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano, 6(1), 410-420.
89. Yang, L., Cui, F., Cun, D., Tao, A., Shi, K., & Lin, W. (2007). Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. International Journal of Pharmaceutics, 340(1-2), 163-172.
90. Yardley, D.A. (2013). nab-Paclitaxel mechanisms of action and delivery. Journal of Controlled Release, 170(3), 365-372.
91. Yedomon, B., Fessi, H., & Charcosset, C. (2013). Preparation of bovine serum albumin (BSA) nanoparticles by desolvation using a membrane contactor: A new tool for large scale production. European Journal of Pharmaceutics and Biopharmaceutics, 85, 398-405.
92. Yu, B., Tai, H. C., Xue, W., Lee, L. J., & Lee, R. J. (2010). Receptor-targeted nanocarriers for therapeutic delivery to cancer. Molecular Membrane Biology, 27(7), 286-298.
93. Zhang, Z., Mei, L., & Feng, S.-S. (2013). Paclitaxel drug delivery systems. Expert Opinion on Drug Delivery, 10(3), 325-340.
94. Zhao, D., Zhao, X., Zu, Y., Li, J., Zhang, Y., Jiang, R., et al. (2010). Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. International Journal of Nanomedicine, 5, 669-677.